GlassScriptPhysician profile
Katherine A Abbott
NPI 1467596932
$283.60
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $25.64 · 2021: $18.31.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $63.27 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.86 | 2019 | |
| Ironshore Pharmaceuticals INC. | $38.56 | 2019 | |
| Neos Therapeutics, LP | $33.66 | 2019 | |
| Glaxosmithkline, LLC. | $18.31 | 2021 | |
| Sanofi Pasteur INC. | $14.73 | 2019 | |
| Shire North American Group INC | $12.92 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.70 | 2019 | |
| Pfizer INC. | $11.82 | 2019 | |
| Sobi, INC | $11.73 | 2019 | |
| Merck Sharp & Dohme LLC | $11.23 | 2019 | |
| Phadia US INC. | $10.81 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Abbott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.